Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic ...( - Activity data on lead NNRTI RDEA806...)

- Activity data on lead NNRTI, RDEA806, and next generation compounds to be

discussed -

CARLSBAD, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that preclinical data on the Company's non-nucleoside reverse transcriptase inhibitor (NNRTI) family of compounds, including RDEA806, RDEA427 and RDEA640, will be presented during the 15th Annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, February 3-6, 2008.

The presentation details are as follows:

Date/Time: Tuesday, February 5, 2008, 1:00 p.m. Eastern Standard Time

Title: An IQ Assessment of RDEA806, A Potent NNRTI with an Excellent

Activity Profile in the Presence of Human Serum Proteins

Location: Poster Session 123 (Poster # 731) -- Hall A, Hynes Convention

Center

Date/Time: Tuesday, February 5, 2008, 1:00 p.m. Eastern Standard Time

Title: RDEA427 and RDEA640 are Novel NNRTIs with Potent Anti-HIV Activity

against NNRTI-Resistance Viruses

Location: Poster Session 123 (Poster # 730) -- Hall A, Hynes Convention

Center

About RDEA806

RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, Ardea believes that RDEA806 possesses several attractive properties. These include: potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R)), Bristol-Myers Squibb) and other currently available NNRTIs; a high genetic barrier to resistance; the potential to be administered in a
'/>"/>